Aspen Aerogels, Inc. (NYSE:ASPN) Receives Average Rating of “Buy” from Brokerages

Aspen Aerogels, Inc. (NYSE:ASPN) has been given a consensus rating of “Buy” by the five ratings firms that are covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $19.00.

ASPN has been the subject of several research analyst reports. Canaccord Genuity Group upped their price target on shares of Aspen Aerogels from $13.00 to $17.00 and gave the company a “buy” rating in a report on Wednesday, December 27th. TheStreet upgraded shares of Aspen Aerogels from a “d+” rating to a “c-” rating in a report on Wednesday, March 6th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Aspen Aerogels in a report on Wednesday, February 14th. Canaccord Genuity Group upped their price target on shares of Aspen Aerogels from $13.00 to $17.00 and gave the company a “buy” rating in a report on Wednesday, December 27th. Finally, Roth Mkm initiated coverage on shares of Aspen Aerogels in a report on Wednesday, March 6th. They issued a “buy” rating and a $22.00 price target for the company.

Aspen Aerogels Stock Up 0.9 %

Shares of NYSE:ASPN opened at $14.96 on Friday. Aspen Aerogels has a 52 week low of $5.32 and a 52 week high of $19.10. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.91 and a current ratio of 3.41. The company has a market capitalization of $1.15 billion, a PE ratio of -22.67 and a beta of 2.04. The company has a 50 day moving average price of $16.46 and a two-hundred day moving average price of $13.02.

Aspen Aerogels (NYSE:ASPN) last issued its earnings results on Tuesday, February 13th. The construction company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.11. Aspen Aerogels had a negative net margin of 19.19% and a negative return on equity of 10.47%. The firm had revenue of $84.22 million during the quarter, compared to the consensus estimate of $83.82 million. During the same quarter in the prior year, the firm earned ($0.20) earnings per share. Analysts forecast that Aspen Aerogels will post -0.24 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Harbour Capital Advisors LLC acquired a new position in Aspen Aerogels during the first quarter worth $404,000. Banque Cantonale Vaudoise boosted its holdings in Aspen Aerogels by 37.5% during the first quarter. Banque Cantonale Vaudoise now owns 4,593 shares of the construction company’s stock worth $81,000 after purchasing an additional 1,252 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Aspen Aerogels by 5.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 12,642 shares of the construction company’s stock worth $200,000 after purchasing an additional 674 shares during the last quarter. Barclays PLC boosted its holdings in Aspen Aerogels by 336.1% during the fourth quarter. Barclays PLC now owns 80,603 shares of the construction company’s stock worth $1,272,000 after purchasing an additional 62,120 shares during the last quarter. Finally, Needham Investment Management LLC lifted its stake in Aspen Aerogels by 17.4% in the fourth quarter. Needham Investment Management LLC now owns 2,967,400 shares of the construction company’s stock valued at $46,826,000 after acquiring an additional 439,100 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Aspen Aerogels Company Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.